MCM
AMPH icon

MAI Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

MAI Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-371
Closed -$7.27K – 2201
2026
Q1 		$7.27K Buy
371
+13
+4% +$318 ﹤0.01% 3319
2025
Q4 		$9.59K Buy
358
+300
+517% +$7.73K ﹤0.01% 2871
2025
Q3 		$1.55K Sell
58
-128
-69% -$3.31K ﹤0.01% 3373
2025
Q2 		$4.27K Buy
+186
New +$4.62K ﹤0.01% 3127

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

MAI Capital Management's AMPH Position: Q2 2026 in Review

MAI Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 371 shares — an estimated $7.27K sold.

MAI Capital Management first reported a position in AMPH in Q2 2025 and held it in 4 quarters. The position peaked at $9.59K in Q4 2025. 211 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • MAI Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 371 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $7.27K.
  • MAI Capital Management first reported a position in Amphastar Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • MAI Capital Management's Amphastar Pharmaceuticals position peaked at $9.59K in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.